The scoringsystem usedin chronicphaseThe current5-yearoverallsurvival rateof CMLWhen togive H2RAswithdasatinibDrug classthatrevolutionizedCMLtreatmentTKIs aremajorsubstratesfor this liverenzymePatients havepresence of thisBCR-ABLproteinindicative ofCML Thelandmarkfor thefirst TKIToo many ofthese bloodcells areabnormal inCML60-70% ofpatients withCML presentwith thissymptomTreatmentfor blastphaseCMLPercentageof blastspresent inthe blastphaseThe numberof distinctclinicalphases inCMLNon-pharmacologicaltreatment forCMLModerateto highemetogenicrisk TKIsTranslocationbetweenthese twochromosomesoccur in CMLI failed 3lines of TKIs,I can try thisagent nextI have theT315I mutationbut also haveelevated lipaseNumber ofblastspresent inacceleratedphaseTherecommendedcriteria usedfor acceleratedphaseI avoid thisdrug classwith bosutinib,nilotinib anddasatinibResponsewhen BCR-ABL1 (IS)is <0.01%I want toavoid thisTKI if I donot wantdiarrheaThis TKI hasthe mostmetabolicsyndromeAfter 3months, I have3% BCR-ABL,I have this TKIresponseThe scoringsystem usedin chronicphaseThe current5-yearoverallsurvival rateof CMLWhen togive H2RAswithdasatinibDrug classthatrevolutionizedCMLtreatmentTKIs aremajorsubstratesfor this liverenzymePatients havepresence of thisBCR-ABLproteinindicative ofCML Thelandmarkfor thefirst TKIToo many ofthese bloodcells areabnormal inCML60-70% ofpatients withCML presentwith thissymptomTreatmentfor blastphaseCMLPercentageof blastspresent inthe blastphaseThe numberof distinctclinicalphases inCMLNon-pharmacologicaltreatment forCMLModerateto highemetogenicrisk TKIsTranslocationbetweenthese twochromosomesoccur in CMLI failed 3lines of TKIs,I can try thisagent nextI have theT315I mutationbut also haveelevated lipaseNumber ofblastspresent inacceleratedphaseTherecommendedcriteria usedfor acceleratedphaseI avoid thisdrug classwith bosutinib,nilotinib anddasatinibResponsewhen BCR-ABL1 (IS)is <0.01%I want toavoid thisTKI if I donot wantdiarrheaThis TKI hasthe mostmetabolicsyndromeAfter 3months, I have3% BCR-ABL,I have this TKIresponse

Chronic Myeloid Leukemia BINGO - Call List

(Print) Use this randomly generated list as your call list when playing the game. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
B
2
I
3
G
4
N
5
I
6
B
7
G
8
N
9
G
10
I
11
B
12
O
13
O
14
G
15
G
16
O
17
N
18
O
19
N
20
I
21
B
22
B
23
O
24
I
  1. B-The scoring system used in chronic phase
  2. I-The current 5-year overall survival rate of CML
  3. G-When to give H2RAs with dasatinib
  4. N-Drug class that revolutionized CML treatment
  5. I-TKIs are major substrates for this liver enzyme
  6. B-Patients have presence of this BCR-ABL protein indicative of CML
  7. G-The landmark for the first TKI
  8. N-Too many of these blood cells are abnormal in CML
  9. G-60-70% of patients with CML present with this symptom
  10. I-Treatment for blast phase CML
  11. B-Percentage of blasts present in the blast phase
  12. O-The number of distinct clinical phases in CML
  13. O-Non-pharmacological treatment for CML
  14. G-Moderate to high emetogenic risk TKIs
  15. G-Translocation between these two chromosomes occur in CML
  16. O-I failed 3 lines of TKIs, I can try this agent next
  17. N-I have the T315I mutation but also have elevated lipase
  18. O-Number of blasts present in accelerated phase
  19. N-The recommended criteria used for accelerated phase
  20. I-I avoid this drug class with bosutinib, nilotinib and dasatinib
  21. B-Response when BCR-ABL1 (IS) is <0.01%
  22. B-I want to avoid this TKI if I do not want diarrhea
  23. O-This TKI has the most metabolic syndrome
  24. I-After 3 months, I have 3% BCR-ABL, I have this TKI response